China's Shrinking Population Poses New Challenge For Pharma
Also, More COVID Drug Approvals
Executive Summary
For the first time in 61 years, China has reported its population is shrinking and the new demographic shift is likely to have a far-reaching impact on the pharma sector. Meanwhile, regulators have accelerated the approval of new COVID-19 drugs to relieve acute shortages.
You may also be interested in...
Cold Water On Already Frozen Sector: Industry Growing Wary Of China Price Cuts
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.
Big Antibody Deals Offer Hope Amid Challenging Times For China Biotech
Recent antibody mega-deals are providing a rare bright spot for the embattled China biotech sector, amid sharply rising COVID-19 deaths in the country that indicate rebound and recovery could take longer than previously expected.
Lockdown To Reopening: China Rebound Uncertain As Biotech Remains In Survival Mode
The short-notice reopening of the country made 2022 a tough year for the health sector in China, where divestments, cash crunches and commercial challenges abounded. Throughout the year, despite clinical trial activity continuing to blossom, multiple Chinese innovative drug developers faced setbacks in the US from regulatory rejections of oncology products. Meanwhile, others quietly scaled back their operations in China, hit by the negative impact of deep price cuts.